Correlation of RECIST, Computed Tomography Morphological Response, and Pathological Regression in Hepatic Metastasis Secondary to Colorectal Cancer: The AVAMET Study.

Background: The prospective phase IV AVAMET study was undertaken to correlate response evaluation criteria in solid tumors (RECIST)-defined response rates with computed tomography-based morphological criteria (CTMC) and pathological response after liver resection of colorectal cancer metastases. Methods: Eligible patients were aged >/=18 years, with Eastern Cooperative Oncology Group (ECOG) performance status 0/1 and histologically-confirmed colon or rectal adenocarcinoma with measurable liver metastases. Preoperative treatment was bevacizumab (7.5 mg on day 1) + XELOX (oxaliplatin 130 mg/m(2), capecitabine 1000 mg/m(2) bid on days 1-14 q3w). After three cycles, response was evaluated by a multidisciplinary team. Patients who were progression-free and metastasectomy candidates received one cycle of XELOX before undergoing surgery 3-5 weeks later, followed by four cycles of bevacizumab + XELOX. Results: A total of 83 patients entered the study; 68 were eligible for RECIST, 67 for CTMC, and 51 for pathological response evaluation. Of these patients, 49% had a complete or partial RECIST response, 91% had an optimal or incomplete CTMC response, and 81% had a complete or major pathological response. CTMC response predicted 37 of 41 pathological responses versus 23 of 41 responses predicted using RECIST (p = 0.008). Kappa coefficients indicated a lack of correlation between the results of RECIST and morphological responses and between morphological and pathological response rates. Conclusion: CTMC may represent a better marker of pathological response to bevacizumab + XELOX than RECIST in patients with potentially-resectable CRC liver metastases

The Pharmacokinetics and Interactions of Ivermectin in Humans—A Mini-review

Ivermectin is an antiparasitic drug with a broad spectrum of activity, high efficacy as well as a wide margin of safety. Since 1987, this compound has a widespread use in veterinary medicine and it use has been extended in humans. Here we present a brief review of the information availabile regarding the pharmacokinetics and interactions of ivermectin in humans. Awareness of these characteristics could improve the clinical efficacy of Ivermectin. All Authors declare that they do not have any Conflict of interest and that the work is original. All Authors agree that the contents of the manuscript are confidential and will not be copyrighted, submitted, or published elsewhere (including the Internet), in any language, while acceptance by the Journal is under consideration

Clonal chromosomal mosaicism and loss of chromosome Y in elderly men increase vulnerability for SARS-CoV-2

The pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2, COVID-19) had an estimated overall case fatality ratio of 1.38% (pre-vaccination), being 53% higher in males and increasing exponentially with age. Among 9578 individuals diagnosed with COVID-19 in the SCOURGE study, we found 133 cases (1.42%) with detectable clonal mosaicism for chromosome alterations (mCA) and 226 males (5.08%) with acquired loss of chromosome Y (LOY). Individuals with clonal mosaic events (mCA and/or LOY) showed a 54% increase in the risk of COVID-19 lethality. LOY is associated with transcriptomic biomarkers of immune dysfunction, pro-coagulation activity and cardiovascular risk. Interferon-induced genes involved in the initial immune response to SARS-CoV-2 are also down-regulated in LOY. Thus, mCA and LOY underlie at least part of the sex-biased severity and mortality of COVID-19 in aging patients. Given its potential therapeutic and prognostic relevance, evaluation of clonal mosaicism should be implemented as biomarker of COVID-19 severity in elderly people. Among 9578 individuals diagnosed with COVID-19 in the SCOURGE study, individuals with clonal mosaic events (clonal mosaicism for chromosome alterations and/or loss of chromosome Y) showed an increased risk of COVID-19 lethality

Satisfaction with social support in the elderly of the district of Bragança

This is a demographic transition scenario with implications in all areas of social life: it is unacceptable to face aging without reflecting on the problems around opportunities for older people, including satisfaction with social support. Social support is particularly important to facilitate an independent and fulfilling life in the community for the elderly. Objectives: To assess the satisfaction of elderly people with social support (individuals aged over 65 years) living in the district of Bragança, by applying a sociodemographic questionnaire and the Satisfaction Scale with Social Support (ESSS) of Ribeiro (2011) [1]. Starting from the elderly population living in Bragança district, we developed an observational, analytical and cross-sectional study with a quantitative approach, with a sample of 517 subjects, mostly females (54.9 %; n = 284); aged between 65 and 74 years old (45.3 %; n = 234); married or living in consensual union (61.9 %; n = 320); residents in rural areas (69.8 %; n = 361); with sons and daughters (89.0 %; n = 460); and illiterate (50.7 %; n = 262). The sample under study has average social support, which allows us to infer that the elderly is, in general, satisfied with the social support which they have, and the support received from friends is that which gives them more satisfaction, expressing less satisfaction with family support. It is observed that most of the variables are, in the case of the elderly, determinants of their satisfaction with social support

[Correspondencia de Camilo Díaz Baliño] , 1917-1936

Mss. (algúns en fotocopia) autógrafo e mecanografiadoResumen: Correspondencia recibida por Camilo Díaz Baliño entre os anos 1917-1936 relacionada con asuntos persoais e laboraisBiblioteca de GaliciaForma de ingreso: Depósito. Fuente de ingreso: Díaz Pardo, Isaac. Fecha de ingreso: 2011. Propietario: Herdeiros de Isaac Díaz PardoDixitalización Telefónica-IDP 2012Contén : Cartas de: Manuel Abelenda (1 páx.) -- Cesar Alvarez (1 páx.) -- Carlos Amigo Collía (2 páxs.) -- Banco Hispano-Americano (2 páxs.) -- Alfonso Barreiro (3 páxs.) -- Eliseo Barros Gamallo (1 páx.),(2 páxs.) -- Ramón Beade (2 páxs.) -- Benito(2 páxs.) -- Fernando Blanco(1 páx.) -- José Bouzas y Cardama (1 páx.) -- Albino Bouzó Fernández (1 páx.),(2 páxs) -- José Cabada Vázquez (4 páxs.),(1 páx.),(1 páx.) --Salvador Cabeza (1 páx.) -- Antonio Carballa (1 páx.) -- Leandro y Euxenio Carré (2 páxs.) -- V. Carro (1 páx.) -- Santiago Casares (1 páx.) -- Alvaro Cebreiro (2 páxs.) -- Centro Gallego de Buenos Aires (1 páx.),(1 páx.) -- Compostela (2 páxs.) -- Manolo: Continental (2 páxs.) -- Coral de Ruada (1 páx.),(2 páxs.) -- Amando Cotarelo(1 páx.),(1 páx.) -- Eduardo Dorado Xaneiro (8 páx.) -- Círculo Mercantil e Idustrial: Ramón Fernández (1 páx.) --Virgilio Fernández(3 páxs.) -- Ramón Fernández Mato (2 páxs.) -- B. Ferreiro(1 páx.) -- Jenaro de la Fuente (1 páx.) -- Isaac Fraga: Espéctaculos Empresa Fraga (1 páx.),(1 páx.) -- Antonio Folgar Lema(1 páx.)--Alicio Garcitoral (1 páx.) -- Cándido González Raño (1 páx.) -- Daniel González Rodriguez (2 páxs.),(2 páxs.) -- Edurardo G.del Río (1 páx.) -- Hermanos Hernández (2 páxs.),(1 páx.),(1 páx.),(1 páx.) -- José Iglesias Sánchez (2 páxs.) -- Irmandades da Fala (1 páx.) -- José Silva? (2 páxs.) -- Arturo Longa (1 páx.) -- Casimiro López (1 páx.) -- Edmundo López (1 páx.),(1 páx.) -- Eduardo R. Losada y Rebellón (2 páx.) -- Carlos Maside (1 páx.) -- Enrique Mayer (1 páx.) -- Antonio Méndez Laserna (1 páx.) -- Anselmo Padín (1 páx.) -- Xavier Pardo (1 páx.) -- Partido Republicano Radical Socialista (1 páx.) -- Pérez Bustamante (1 páx.) -- Modesto Piñeiro (2 páxs.) -- Salustiano Portela (2 páxs.) -- José Seijo Rubio (2 páxs.) -- Suarez Picallo (2 páxs.) -- Luis Losada (1 páx), (1 páx.) -- Ricardo Valdés (2 páxs.),(2 páxs.),(2 páxs.),(1 páx.) -- A.Nilo Varela (1 páx.),(2 páxs.),(2 páxs.) -- Juan Varela de Limia (1 páx.) -- Victorino? Varela (1 páx.) -- Jesús Varela (3 páxs.) -- F.Vázquez Suarez (1 páx.) -- Santiago Vidal Gimeno (1 páx.) -- Pedro Vieitez (1 páx.) -- M. Villar (2 páxs.) -- Anónima (1 páx.) -- Anónima (1 páx.

Mutational spectrum of dystrophinopathies in Singapore: Insights for genetic diagnosis and precision therapy

10.1002/ajmg.c.31704AMERICAN JOURNAL OF MEDICAL GENETICS PART C-SEMINARS IN MEDICAL GENETICS1812230-24

GWAS and meta-analysis identifies 49 genetic variants underlying critical COVID-19

Data availability: Downloadable summary data are available through the GenOMICC data site (https://genomicc.org/data). Summary statistics are available, but without the 23andMe summary statistics, except for the 10,000 most significant hits, for which full summary statistics are available. The full GWAS summary statistics for the 23andMe discovery dataset will be made available through 23andMe to qualified researchers under an agreement with 23andMe that protects the privacy of the 23andMe participants. For further information and to apply for access to the data, see the 23andMe website (https://research.23andMe.com/dataset-access/). All individual-level genotype and whole-genome sequencing data (for both academic and commercial uses) can be accessed through the UKRI/HDR UK Outbreak Data Analysis Platform (https://odap.ac.uk). A restricted dataset for a subset of GenOMICC participants is also available through the Genomics England data service. Monocyte RNA-seq data are available under the title ‘Monocyte gene expression data’ within the Oxford University Research Archives (https://doi.org/10.5287/ora-ko7q2nq66). Sequencing data will be made freely available to organizations and researchers to conduct research in accordance with the UK Policy Framework for Health and Social Care Research through a data access agreement. Sequencing data have been deposited at the European Genome–Phenome Archive (EGA), which is hosted by the EBI and the CRG, under accession number EGAS00001007111.Extended data figures and tables are available online at https://www.nature.com/articles/s41586-023-06034-3#Sec21 .Supplementary information is available online at https://www.nature.com/articles/s41586-023-06034-3#Sec22 .Code availability: Code to calculate the imputation of P values on the basis of SNPs in linkage disequilibrium is available at GitHub (https://github.com/baillielab/GenOMICC_GWAS).Acknowledgements: We thank the members of the Banco Nacional de ADN and the GRA@CE cohort group; and the research participants and employees of 23andMe for making this work possible. A full list of contributors who have provided data that were collated in the HGI project, including previous iterations, is available online (https://www.covid19hg.org/acknowledgements).Change history: 11 July 2023: A Correction to this paper has been published at: https://doi.org/10.1038/s41586-023-06383-z. -- In the version of this article initially published, the name of Ana Margarita Baldión-Elorza, of the SCOURGE Consortium, appeared incorrectly (as Ana María Baldion) and has now been amended in the HTML and PDF versions of the article.Copyright © The Author(s) 2023, Critical illness in COVID-19 is an extreme and clinically homogeneous disease phenotype that we have previously shown1 to be highly efficient for discovery of genetic associations2. Despite the advanced stage of illness at presentation, we have shown that host genetics in patients who are critically ill with COVID-19 can identify immunomodulatory therapies with strong beneficial effects in this group3. Here we analyse 24,202 cases of COVID-19 with critical illness comprising a combination of microarray genotype and whole-genome sequencing data from cases of critical illness in the international GenOMICC (11,440 cases) study, combined with other studies recruiting hospitalized patients with a strong focus on severe and critical disease: ISARIC4C (676 cases) and the SCOURGE consortium (5,934 cases). To put these results in the context of existing work, we conduct a meta-analysis of the new GenOMICC genome-wide association study (GWAS) results with previously published data. We find 49 genome-wide significant associations, of which 16 have not been reported previously. To investigate the therapeutic implications of these findings, we infer the structural consequences of protein-coding variants, and combine our GWAS results with gene expression data using a monocyte transcriptome-wide association study (TWAS) model, as well as gene and protein expression using Mendelian randomization. We identify potentially druggable targets in multiple systems, including inflammatory signalling (JAK1), monocyte–macrophage activation and endothelial permeability (PDE4A), immunometabolism (SLC2A5 and AK5), and host factors required for viral entry and replication (TMPRSS2 and RAB2A).GenOMICC was funded by Sepsis Research (the Fiona Elizabeth Agnew Trust), the Intensive Care Society, a Wellcome Trust Senior Research Fellowship (to J.K.B., 223164/Z/21/Z), the Department of Health and Social Care (DHSC), Illumina, LifeArc, the Medical Research Council, UKRI, a BBSRC Institute Program Support Grant to the Roslin Institute (BBS/E/D/20002172, BBS/E/D/10002070 and BBS/E/D/30002275) and UKRI grants MC_PC_20004, MC_PC_19025, MC_PC_1905 and MRNO2995X/1. A.D.B. acknowledges funding from the Wellcome PhD training fellowship for clinicians (204979/Z/16/Z), the Edinburgh Clinical Academic Track (ECAT) programme. This research is supported in part by the Data and Connectivity National Core Study, led by Health Data Research UK in partnership with the Office for National Statistics and funded by UK Research and Innovation (grant MC_PC_20029). Laboratory work was funded by a Wellcome Intermediate Clinical Fellowship to B.F. (201488/Z/16/Z). We acknowledge the staff at NHS Digital, Public Health England and the Intensive Care National Audit and Research Centre who provided clinical data on the participants; and the National Institute for Healthcare Research Clinical Research Network (NIHR CRN) and the Chief Scientist’s Office (Scotland), who facilitate recruitment into research studies in NHS hospitals, and to the global ISARIC and InFACT consortia. GenOMICC genotype controls were obtained using UK Biobank Resource under project 788 funded by Roslin Institute Strategic Programme Grants from the BBSRC (BBS/E/D/10002070 and BBS/E/D/30002275) and Health Data Research UK (HDR-9004 and HDR-9003). UK Biobank data were used in the GSMR analyses presented here under project 66982. The UK Biobank was established by the Wellcome Trust medical charity, Medical Research Council, Department of Health, Scottish Government and the Northwest Regional Development Agency. It has also had funding from the Welsh Assembly Government, British Heart Foundation and Diabetes UK. The work of L.K. was supported by an RCUK Innovation Fellowship from the National Productivity Investment Fund (MR/R026408/1). J.Y. is supported by the Westlake Education Foundation. SCOURGE is funded by the Instituto de Salud Carlos III (COV20_00622 to A.C., PI20/00876 to C.F.), European Union (ERDF) ‘A way of making Europe’, Fundación Amancio Ortega, Banco de Santander (to A.C.), Cabildo Insular de Tenerife (CGIEU0000219140 ‘Apuestas científicas del ITER para colaborar en la lucha contra la COVID-19’ to C.F.) and Fundación Canaria Instituto de Investigación Sanitaria de Canarias (PIFIISC20/57 to C.F.). We also acknowledge the contribution of the Centro National de Genotipado (CEGEN) and Centro de Supercomputación de Galicia (CESGA) for funding this project by providing supercomputing infrastructures. A.D.L. is a recipient of fellowships from the National Council for Scientific and Technological Development (CNPq)-Brazil (309173/2019-1 and 201527/2020-0)